Full-Time

Production Technician 1

Deadline 8/5/27
Genus

Genus

1,001-5,000 employees

Global animal genetics and breeding technology

Compensation Overview

$19.25/hr

Mound City, SD, USA

In Person

Category
Medical, Clinical & Veterinary (1)

Get referred to Genus

See people who can refer or advise you

Requirements
  • Previous livestock handling experience is preferred.
  • Ability to work both autonomously and within a team environment.
  • Ability to follow instructions and deal with standardized situations.
  • Ability to work in and maintain performance expectations in a fast-paced environment.
  • Attention to detail and ability to meet deadlines.
  • Minimal, if any, travel is required.
Responsibilities
  • Accomplish daily department work requirements and farm goals as part of the team.
  • Perform daily animal husbandry tasks.
  • Maintain accurate and timely production information and records.
  • Assist in moving animals and maintaining efficient animal flows.
  • Treat sick animals with pharmaceuticals by injection, oral application, or other required methods.
  • Maintain barns by sanitizing and washing multiple farm areas with high-pressure equipment, and perform office-cleanliness and laundry duties.
  • Follow farm leadership directions when plans change.
  • Follow animal-care policies and procedures, including providing suitable physical conditions, adequate water and high-quality feed, humane treatment, identification and appropriate treatment of animals requiring care, and euthanasia guidelines.
  • Read and understand the emergency notification process and its application to the worksite.
  • Follow company policies, procedures, and guidelines, including safety requirements, biosecurity protocols, and environmental laws and procedures.
  • Report environmental issues immediately to the supervisor.
Desired Qualifications
  • Previous livestock handling experience.

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 interim results on 26 February 2026 showed record first-half adjusted operating profit.
  • ABS grew genotyping above 30% on 7 May 2026, signaling commercial momentum.
  • 50 million Sexcel units sold by 25 June 2026 proves global scaling.

What critics are saying

  • PIC China deconsolidation removes reported revenue, and 49% ownership cuts control.
  • Genus still depends on regulators in Mexico, Japan, and China for commercialization.
  • If export markets block gene-edited pork, PRRS commercialization stays stranded indefinitely.

What makes Genus unique

  • Genus owns PIC and ABS, spanning pig and bovine genetics globally.
  • Canada approved PRRS-resistant pigs on 23 January 2026, validating its gene-editing moat.
  • The 31 January 2026 China JV with BCA preserves royalties while de-risking exposure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Parental Leave

Employee Stock Purchase Plan

Paid Holidays

Paid Vacation

Tuition Reimbursement

Flexible Work Hours

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT